[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Simsek I, Pay S, Dinc A, Erdem H, Kurt B: Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report. Clin Rheumatol; 2007 Sep;26(9):1561-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.
  • Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy.
  • We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis.
  • This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Carcinoid Tumor / chemically induced. Immunoglobulin G / adverse effects. Thymus Neoplasms / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Etanercept. Humans. Male. Pituitary ACTH Hypersecretion / etiology. Receptors, Tumor Necrosis Factor. Spondylarthritis / drug therapy

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2003 Jul;124(1):141-6 [12853516.001]
  • [Cites] Ann Rheum Dis. 2005 May;64(5):699-703 [15695534.001]
  • [Cites] Drug Saf. 2004;27(5):307-24 [15061685.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1651-5 [15933793.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5 Suppl):S75-7 [15097933.001]
  • [Cites] Rheumatology (Oxford). 2003 Jul;42(7):900-1 [12826706.001]
  • [Cites] J Rheumatol. 2002 Jan;29(1):118-22 [11824947.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • (PMID = 17061154.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; OP401G7OJC / Etanercept
  •  go-up   go-down


2. Auer J, Kirchgatterer A, Berent R, Allinger S, Hinterholzer G, Höbling W, Meindl S, Oppitz P, Kalchmair J, Neuwirth G, Knoflach P: [Gastrointestinal hemorrhage needing blood transfusion as the first manifestation of small bowel carcinoid tumor]. Z Gastroenterol; 2000 Aug;38(8):631-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal hemorrhage needing blood transfusion as the first manifestation of small bowel carcinoid tumor].
  • Carcinoid tumors arise from enterochromaffin or enterochromaffin-like cells that are present in the gastrointestinal tract, ovaries, and lungs.
  • Carcinoid syndrome is associated with small intestine carcinoids in about 40%.
  • Upper gastrointestinal bleeding with melaena or hematochezia is a relatively rare early symptom of patients with small intestine carcinoid tumors.
  • Laparotomy revealed bleeding from a small submucosal malignant carcinoid tumor in small intestine and multiple large metastases within mesenteric tissue.
  • Small intestinal carcinoid tumor has to be considered as a rare cause of gastrointestinal bleeding with melaena or hematochezia.
  • Nevertheless, bleeding is a relatively rare early symptom of patients with small intestine carcinoid tumor.
  • [MeSH-major] Blood Transfusion. Carcinoid Tumor / diagnosis. Gastrointestinal Hemorrhage / etiology. Intestinal Neoplasms / diagnosis. Intestine, Small
  • [MeSH-minor] Acenocoumarol / administration & dosage. Acenocoumarol / adverse effects. Aged. Diagnosis, Differential. Humans. Male. Protein S Deficiency / drug therapy. Protein S Deficiency / genetics. Recurrence


3. Takahashi T, Hatao K, Yamashita Y, Tanizawa Y: Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide. Intern Med; 2003 Dec;42(12):1197-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide.
  • A 21-year-old woman with Cushing's syndrome presented with a mediastinal tumor.
  • Ectopic ACTH syndrome was diagnosed and the tumor was resected.
  • The histopathological diagnosis was thymic atypical carcinoid.
  • Despite all tumor lesions having been resected, the tumor relapsed and multiple metastatic lesions grew aggressively.
  • Combination chemotherapy with cisplatin and etoposide (VP16) was administered to control tumor progression, and achieved marked therapeutic effects.
  • Maintenance chemotherapy with carboplatin and VP16 achieved long-term tumor control.
  • This case indicates that some patients with atypical carcinoid tumor are good responders to chemotherapy with platinum agents and VP16.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy. Cisplatin / administration & dosage. Etoposide / administration & dosage. Thymus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoid Syndrome.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14714958.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Berndt A, Köllner R, Richter P, Franz M, Voigt A, Berndt A, Borsi L, Giavazzi R, Neri D, Kosmehl H: A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol; 2010 Apr;133(4):467-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.
  • Tumour angioneogenesis is associated with the reexpression of oncofetal fibronectin (oncFn) and tenascin-C (oncTn-C) splice variants, which may serve as targets for antibody-based pharmacodelivery.
  • Knowledge of the vascular distribution and organization in different tumours is of importance for the understanding of tumour vessel formation and might be crucial for therapy.
  • Renal cell carcinomas and atypical carcinoid of the lung revealed vessel-restricted oncFn and/or oncTn-C depositions; all other entities showed a variable stroma positivity including vessels.
  • The individual pattern of oncFn/oncTn-C incorporation in the vBM depended on tumour type, vessel size and intratumoural heterogeneity.
  • In conclusion, tumours differ in the pattern of Fn or Tn-C isoform positivity in the vessel wall, potentially representing a tumour type specific endothelial cell-tumour cell-stromal cell interaction.
  • Up to antigen distribution, Fn and Tn-C domain antibodies may serve as vehicles for antiangiogenetic and antifibrotic agents; oncFn/oncTn-C based targeting should be adapted individually.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Cancer Drug Targets. 2008 Sep;8(6):447-53 [18781891.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6021-5 [12414622.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):1-17 [17661033.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):311-22 [8982375.001]
  • [Cites] J Oral Pathol Med. 2007 Jan;36(1):6-11 [17181735.001]
  • [Cites] FASEB J. 2006 Apr;20(6):717-9 [16461331.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):29012-7 [7499434.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):143-63 [16632194.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Mar;20(1):21-4 [11370824.001]
  • [Cites] Dev Biol. 1997 Sep 15;189(2):285-300 [9299121.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Oct;135(10):1351-8 [19326143.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5476-84 [12359756.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Mol Hum Reprod. 1999 Nov;5(11):1066-76 [10541570.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1862-70 [17519905.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):153-61 [18221033.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Nature. 1984 Sep 20-26;311(5983):267-9 [6482952.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2265-74 [19131554.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2405-13 [18271006.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2660-8 [11980665.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] J Histochem Cytochem. 2002 Aug;50(8):1113-30 [12133914.001]
  • [Cites] FEBS Lett. 1993 Oct 11;332(1-2):39-43 [7691659.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1105-13 [8822112.001]
  • [Cites] Histochem J. 1995 Dec;27(12):1014-20 [8789403.001]
  • [Cites] Bioessays. 1991 Oct;13(10):527-33 [1755828.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2082-90 [17404090.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Histopathology. 2007 Dec;51(6):849-53 [18042073.001]
  • [Cites] Angiogenesis. 2009;12(2):165-75 [19219555.001]
  • [Cites] Histochem Cell Biol. 1998 Mar;109(3):249-55 [9541473.001]
  • [Cites] Biol Pharm Bull. 2008 May;31(5):1003-7 [18451535.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4384-92 [12933583.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):28-33 [18799229.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2275-83 [19005180.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):711-6 [11212273.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):347-52 [9927045.001]
  • [Cites] Curr Pharm Des. 2009;15(12):1385-400 [19355976.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Blood. 1999 Jul 1;94(1):192-8 [10381513.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):885-92 [15729726.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):612-8 [7525495.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):735-54 [16822576.001]
  • [Cites] Anat Rec. 2001 Dec 1;264(4):317-24 [11745087.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Protein Eng Des Sel. 2006 Oct;19(10):471-8 [16928692.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Aug;36(8):671-9 [17643963.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1235-44 [19259661.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Aug;132(8):537-46 [16788848.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):264-9 [11875427.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] EMBO J. 1987 Aug;6(8):2337-42 [2822387.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • [Cites] Curr Opin Genet Dev. 2009 Feb;19(1):67-73 [19211240.001]
  • [Cites] Genes Dev. 2008 May 1;22(9):1231-43 [18451110.001]
  • (PMID = 20237793.001).
  • [ISSN] 1432-119X
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Laminin; 0 / Protein Isoforms; 0 / Tenascin; 0 / oncofetal fibronectin
  •  go-up   go-down


5. Davì MV, Bodei L, Francia G, Bartolomei M, Oliani C, Scilanga L, Reghellin D, Falconi M, Paganelli G, Lo Cascio V, Ferdeghini M: Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest; 2006 Jun;29(6):563-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
  • It is well known that some procedures performed in diagnostic and therapeutic management of endocrine tumors, such as agobiopsy and hepatic chemoembolization, can be associated with the occurrence of symptoms related to the release of vasoactive amines and/or hormonal peptides from tumor cell lysis.
  • This is the first report of a severe carcinoid crisis developed after receptor radionuclide therapy with 90Y-DOTATOC administered in a patient affected by liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
  • The patient received iv infusion of octreotide associated with H1 and H2 receptor antagonists and corticosteroid therapy, which induced symptom remission within few days.
  • The case here reported confirms that radionuclide therapy is highly effective in determining early rupture of metastatic tissue and also suggests that pre-medication should be implemented before the radiopeptide administration associated with a close monitoring of the patient in the following days.
  • [MeSH-major] Bronchial Neoplasms / pathology. Liver Neoplasms / secondary. Malignant Carcinoid Syndrome / chemically induced. Octreotide / analogs & derivatives
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Carcinoid Tumor / drug therapy. Carcinoid Tumor / radiotherapy. Humans. Male. Yttrium Radioisotopes / adverse effects

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):231-42 [12735141.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46 [15150675.001]
  • [Cites] Br J Anaesth. 2001 Sep;87(3):447-52 [11517130.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):133-40 [11965608.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):207-16 [12552338.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Feb;17(3):437-44 [12562458.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23 (4):412-5 [10955874.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):141-7 [11965609.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):426-34 [11357492.001]
  • (PMID = 16840837.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 90Y-octreotide, DOTA-Tyr(3)-; 0 / Yttrium Radioisotopes; RWM8CCW8GP / Octreotide
  •  go-up   go-down


6. Thomas R, Christopher DJ, Balamugesh T, Shah A: Clinico-pathologic study of pulmonary carcinoid tumours--a retrospective analysis and review of literature. Respir Med; 2008 Nov;102(11):1611-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic study of pulmonary carcinoid tumours--a retrospective analysis and review of literature.
  • OBJECTIVE: To determine the characteristic clinico-pathologic features of pulmonary carcinoid tumours in India.
  • METHODS: Retrospective analysis of the clinico-pathologic and radiologic data of patients with pulmonary carcinoid tumours from the department of Pulmonary Medicine of the Christian Medical College, a tertiary care teaching hospital in Southern India, over a study period of 3 years (2001-2004).
  • RESULTS: There were 25 cases of pulmonary carcinoid tumours: typical 22 (88%) and atypical 3 (12%).
  • There were 3 smokers (all of whom were males) in the typical carcinoid group and none in the atypical carcinoid group.
  • Carcinoid syndrome was not present in any patient.
  • Diagnosis was made by flexible bronchoscopy and bronchial biopsy in 23 patients (92%).
  • The tumour bled significantly following biopsy in most patients; however, there was no mortality, and only 1 patient required blood transfusion.
  • CONCLUSION: The clinico-pathologic and radiologic features of pulmonary carcinoid tumours are presented.
  • We report the first series of pulmonary carcinoid tumours from India.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614346.001).
  • [ISSN] 1532-3064
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


7. Hubalewska-Dydejczyk A, Fröss-Baron K, Gołkowski F, Sowa-Staszczak A, Mikołajczak R, Huszno B: 99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid. Exp Clin Endocrinol Diabetes; 2007 Jan;115(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid.
  • SRS holds great promise for detecting occult primary tu and metastatic lesions. (99m)Tc-EDDA/HYNIC-octreotate, a new scintigraphic agent, should significantly improve sensitivity of the diagnostics of carcinoids due to better affinity to SSR2 than (111)In-Octreoscan and the higher count rate obtained from (99m)Tc over (111)In.
  • We present a case of a 40-year-old women operated on because of lung carcinoid tumour in 2002.
  • Owing to severe bone pains and carcinoid symptoms the patient was referred for the 90Y-DOTA-octreotate treatment.
  • CONCLUSIONS: SRS with a new 99mTc marked somatostatin analogue - octreotate allows for a more sensitive detection of metastatic leasions in carcinoid tumours.
  • The usefulness of 18F-FDG PET, widely used as a powerful imaging technique in clinical oncology, is limited in detection of carcinoid tumours due to the low proliferative activity.
  • [MeSH-major] Carcinoid Tumor / radiography. Lung Neoplasms / radiography. Mediastinal Neoplasms / radiography. Radiopharmaceuticals / administration & dosage
  • [MeSH-minor] Adult. Edetic Acid / administration & dosage. Edetic Acid / analogs & derivatives. Female. Humans. Hydrazines. Neoplasm Metastasis. Nicotinic Acids. Organotechnetium Compounds / administration & dosage. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17286235.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 6-hydrazinopyridine-3-carboxylic acid; 0 / Hydrazines; 0 / Nicotinic Acids; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 51110-01-1 / Somatostatin; 5657-17-0 / EDDA; 9G34HU7RV0 / Edetic Acid; G083B71P98 / pentetreotide
  •  go-up   go-down


8. Spaggiari L, D' Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, de Braud F: Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg; 2005 Jan;79(1):234-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The were 10 squamous cell carcinomas (60%), 2 adenocarcinomas, 1 adenosquamous carcinoma, 1 mucoepidermoid carcinoma, and 1 atypical carcinoid tumor.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Antineoplastic Agents / therapeutic use. Arrhythmias, Cardiac / epidemiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass. Combined Modality Therapy. Databases, Factual. Female. Humans. Length of Stay / statistics & numerical data. Life Tables. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620949.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


9. Meyers MO, Anthony LB, McCarthy KE, Drouant G, Maloney TJ, Espanan GD, Woltering EA: High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J; 2000 Aug;93(8):809-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.
  • Our 35-year-old patient had atypical carcinoid tumor metastatic to cervical, supraclavicular, mediastinal, and mesenteric lymph nodes and to the liver and bone.
  • After a diagnostic 111In-pentetreotide scan, the patient was given eight courses (180 mCi each) of 111In-pentetreotide therapy to selectively target somatostatin receptor-expressing tumor cells.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Carcinoid Tumor / radiotherapy. Carcinoid Tumor / secondary. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Lymphatic Metastasis / radiotherapy. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Receptors, Somatostatin / analysis. Receptors, Somatostatin / drug effects

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10963516.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; 6PLQ3CP4P3 / Etoposide; G083B71P98 / pentetreotide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement